n°110

November 2010

Issue Contents
Editorial

Free  It’s official... but not infallible

p.244
EU and US regulators diverge on maraviroc

Marketing Authorisations

Icatibant (attacks of hereditary angioedema) (New Drug)

p.245-247
Continue to use C1 esterase inhibitor

Raltegravir (first-line therapy for HIV infection)(New Indication)

p.248-250
No evidence of comparative effectiveness

Orlistat without a prescription (Labelling Change)

p.250
The SPC now contains more situations where patients are advised to consult a doctor

INN common stems : -azoline

p.250

Fentanyl intranasal (breakthrough cancer pain)(New Formulation)

p.251
Unsafe packaging

Maraviroc (first-line therapy for HIV infection)(Off Label)

p.252-254
Too risky

Adverse Effects

Immunoallergic adverse effects of fluindione

p.255-256
Do not start treatment with fluindione, use warfarin instead

Painful chronic ulceration linked with nicorandil: the vagina too

p.257
Patients should no longer be exposed to nicorandil

Topical tacrolimus and pimecrolimus: cancer, infections

p.257
New Information on worrying cases reported in the US

Reviews

Aspirin and primary cardiovascular prevention

p.258-261
Uncertain balance between benefits and risks

Buruli ulcer

p.261-262
A disabling infection

Outlook

Guideline Watch - Confusing French guidelines on the management of agitation in confused elderly patients

p.263
Useless guideline

Letters - Stable angina: role of ivabradine unchanged between 2006 and 2010

p.264-265
Do not use ivabradine

Free  Letters - Ulipristal and postcoital contraception

p.265-266
HRA Pharma is not happy but fails to cite so-called errors and omissions in Prescrire assessment

Free  Prescrire International now published 11 times a year

p.268

Masthead

Free  Masthead

p.242

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe